BioCentury
ARTICLE | Clinical News

EPC2407: Interim Phase I data

April 14, 2008 7:00 AM UTC

In an ongoing open-label, U.S. Phase I trial, intravenous EPC2407 stabilized disease in 7 out of 8 evaluable patients who received 4, 8 and 13 mg/kg of EPC2407 for up to 5 cycles. Overall blood perfus...